JP2012526832A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526832A5 JP2012526832A5 JP2012510964A JP2012510964A JP2012526832A5 JP 2012526832 A5 JP2012526832 A5 JP 2012526832A5 JP 2012510964 A JP2012510964 A JP 2012510964A JP 2012510964 A JP2012510964 A JP 2012510964A JP 2012526832 A5 JP2012526832 A5 JP 2012526832A5
- Authority
- JP
- Japan
- Prior art keywords
- transnorsertraline
- pharmaceutical composition
- serotonin receptor
- disorder
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims 7
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000005557 antagonist Substances 0.000 claims 5
- 239000000556 agonist Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000036651 mood Effects 0.000 claims 3
- XIGAHNVCEFUYOV-BTJKTKAUSA-N (z)-but-2-enedioic acid;n-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-n-pyridin-2-ylcyclohexanecarboxamide Chemical compound OC(=O)\C=C/C(O)=O.COC1=CC=CC=C1N1CCN(CCN(C(=O)C2CCCCC2)C=2N=CC=CC=2)CC1 XIGAHNVCEFUYOV-BTJKTKAUSA-N 0.000 claims 2
- NRPQELCNMADTOZ-OAQYLSRUSA-N 4-cyano-n-[(2r)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-n-pyridin-2-ylbenzamide Chemical compound C([C@@H](C)N1CCN(CC1)C=1C=2OCCOC=2C=CC=1)N(C=1N=CC=CC=1)C(=O)C1=CC=C(C#N)C=C1 NRPQELCNMADTOZ-OAQYLSRUSA-N 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical group C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims 2
- 229960002495 buspirone Drugs 0.000 claims 2
- SRPXSILJHWNFMK-MEDUHNTESA-N dasotraline Chemical group C1([C@@H]2CC[C@H](C3=CC=CC=C32)N)=CC=C(Cl)C(Cl)=C1 SRPXSILJHWNFMK-MEDUHNTESA-N 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- WVLHGCRWEHCIOT-UHFFFAOYSA-N eltoprazine Chemical compound C1CNCCN1C1=CC=CC2=C1OCCO2 WVLHGCRWEHCIOT-UHFFFAOYSA-N 0.000 claims 2
- 229950006047 eltoprazine Drugs 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 229950007396 lecozotan Drugs 0.000 claims 2
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical group CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims 2
- 229960002508 pindolol Drugs 0.000 claims 2
- 208000012672 seasonal affective disease Diseases 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 claims 2
- 229950000505 tandospirone Drugs 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000001457 vasomotor Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17799709P | 2009-05-13 | 2009-05-13 | |
| US61/177,997 | 2009-05-13 | ||
| PCT/US2010/034473 WO2010132521A1 (en) | 2009-05-13 | 2010-05-12 | Compositions comprising transnorsertraline and serotonin receptor 1a agonists/ antagonists and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015113773A Division JP2015180673A (ja) | 2009-05-13 | 2015-06-04 | トランスノルセルトラリン及びセロトニン受容体１ａ作動剤／拮抗剤を含む組成物及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012526832A JP2012526832A (ja) | 2012-11-01 |
| JP2012526832A5 true JP2012526832A5 (enExample) | 2013-06-27 |
Family
ID=42306730
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012510964A Pending JP2012526832A (ja) | 2009-05-13 | 2010-05-12 | トランスノルセルトラリン及びセロトニン受容体１ａ作動剤／拮抗剤を含む組成物及びその使用 |
| JP2015113773A Pending JP2015180673A (ja) | 2009-05-13 | 2015-06-04 | トランスノルセルトラリン及びセロトニン受容体１ａ作動剤／拮抗剤を含む組成物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015113773A Pending JP2015180673A (ja) | 2009-05-13 | 2015-06-04 | トランスノルセルトラリン及びセロトニン受容体１ａ作動剤／拮抗剤を含む組成物及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20120077818A1 (enExample) |
| EP (1) | EP2429514A1 (enExample) |
| JP (2) | JP2012526832A (enExample) |
| CN (1) | CN102573823B (enExample) |
| CA (1) | CA2759180A1 (enExample) |
| WO (1) | WO2010132521A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8134029B2 (en) | 2002-09-16 | 2012-03-13 | Sunovion Pharmaceuticals Inc. | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine |
| WO2007006003A2 (en) | 2005-07-06 | 2007-01-11 | Sepracor Inc. | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
| WO2011064769A1 (en) * | 2009-11-24 | 2011-06-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and pharmaceutical compositions for the treatment of hot flashes |
| DK2506842T3 (en) * | 2009-12-04 | 2015-02-23 | Sunovion Pharmaceuticals Inc | Formulations, salts and polymorphs of transnorsertraline and their applications |
| JP6436024B2 (ja) | 2015-09-14 | 2018-12-12 | 住友電気工業株式会社 | 炭化珪素エピタキシャル基板の製造方法 |
| WO2019143920A1 (en) * | 2018-01-19 | 2019-07-25 | Sunovion Pharmaceuticals Inc. | Oral dosage forms |
| WO2019182915A1 (en) * | 2018-03-19 | 2019-09-26 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of depression |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| US20210386689A1 (en) * | 2018-10-31 | 2021-12-16 | Sunovion Pharmaceuticals Inc. | Methods of treating central nervous system disorders |
| WO2025049588A1 (en) * | 2023-08-29 | 2025-03-06 | The Trustees Of Indiana University | Novel treatments for optic neuropathies and glaucoma |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5810518A (ja) * | 1981-07-14 | 1983-01-21 | Kowa Yakuhin Kogyo Kk | アルコ−ル中毒または鎮静催眠薬中毒治療剤 |
| US4634703A (en) * | 1985-10-25 | 1987-01-06 | Bristol-Myers Company | Method for alleviation of panic disorders |
| US4687772A (en) * | 1986-10-07 | 1987-08-18 | Bristol-Myers Company | Method for improvement of short term memory |
| US4777173A (en) * | 1987-03-25 | 1988-10-11 | Bristol-Myers Company | Method for treatment of alcohol abuse |
| US5468749A (en) * | 1988-08-30 | 1995-11-21 | Gawin; Frank H. | Method for treatment of substance addiction |
| IL91451A0 (en) * | 1988-08-30 | 1990-04-29 | Bristol Myers Co | Pharmaceutical compositions comprising azapiron compounds and their use in the treatment of addiction |
| IL97054A (en) * | 1990-02-12 | 1995-10-31 | Bristol Meyers Squibb Co | Pharmaceutical preparations containing bospirone for the treatment of coma |
| JPH03246225A (ja) * | 1990-02-20 | 1991-11-01 | Bristol Myers Squibb Co | メランコリーうつ病の治療法 |
| JPH04327532A (ja) * | 1991-01-31 | 1992-11-17 | Bristol Myers Squibb Co | 活動過剰を伴う注意力欠乏疾患の治療に使用する医薬製剤 |
| US5858407A (en) * | 1992-02-27 | 1999-01-12 | Alza Corporation | Method for administering tandospirone |
| US5330762A (en) * | 1992-02-27 | 1994-07-19 | Alza Corporation | Tandospiaine antidepressive therapy |
| ATE192042T1 (de) * | 1995-08-16 | 2000-05-15 | Lilly Co Eli | Potenzierung von serotonin-wirkstoffresponz |
| EP0792649A1 (en) * | 1996-02-29 | 1997-09-03 | Eli Lilly And Company | Treatment of sleep disorders |
| EP0818198A1 (en) * | 1996-07-09 | 1998-01-14 | Lilly S.A. | Potentiation of drug response by increasing serotonin availability |
| US6500827B2 (en) * | 1998-05-08 | 2002-12-31 | Pharmacia & Upjohn Company | Drug combinations |
| HUP0101341A3 (en) * | 1998-05-08 | 2006-07-28 | Upjohn Co | New drug combinations |
| JP2002020291A (ja) * | 2000-06-30 | 2002-01-23 | Sumitomo Pharmaceut Co Ltd | 認知機能障害の治療剤 |
| EP1383496B1 (en) * | 2001-02-20 | 2008-10-01 | Dinan, Timothy Gerard | Treatment of fibromyalgia using pindolol |
| US20020183306A1 (en) * | 2001-05-30 | 2002-12-05 | Pfizer Inc. | Combination treatment for sleep disorders including sleep apnea |
| ES2323451T7 (es) * | 2001-07-20 | 2011-08-01 | Psychogenics Inc. | Tratamiento para el trastorno de hiperactividad con deficit de atencion. |
| JP2003335678A (ja) * | 2002-05-17 | 2003-11-25 | Sumitomo Pharmaceut Co Ltd | 神経因性疼痛治療薬 |
| PT1542961E (pt) * | 2002-09-16 | 2013-11-05 | Sunovion Pharmaceuticals Inc | Trans 4-(3,4-diclorofenil)-1,2,3,4-tetrahidro-1- naftalenamina para uso no tratamento de perturbações do sistema nervoso central |
| WO2006030306A2 (en) * | 2004-09-17 | 2006-03-23 | Neurocure Ltd | Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder |
| US20080262071A1 (en) * | 2004-09-17 | 2008-10-23 | Timothy Dinan | Pindolol for the Treating Premenstrual Syndrome and Premenstrual Dysphoric Disorder |
| WO2007006003A2 (en) * | 2005-07-06 | 2007-01-11 | Sepracor Inc. | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
| PE20070334A1 (es) * | 2005-09-09 | 2007-05-08 | Wyeth Corp | Composiciones y formas de dosificacion farmaceuticas que comprende lecozotan |
| JP2009538925A (ja) * | 2006-05-31 | 2009-11-12 | セプラコール， インク． | ｔｒａｎｓ４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミン及びそのホルムアミドを用いる疼痛性障害の治療 |
-
2010
- 2010-05-12 CA CA2759180A patent/CA2759180A1/en not_active Abandoned
- 2010-05-12 EP EP10719204A patent/EP2429514A1/en not_active Withdrawn
- 2010-05-12 CN CN201080019852.5A patent/CN102573823B/zh not_active Expired - Fee Related
- 2010-05-12 US US13/320,246 patent/US20120077818A1/en not_active Abandoned
- 2010-05-12 JP JP2012510964A patent/JP2012526832A/ja active Pending
- 2010-05-12 WO PCT/US2010/034473 patent/WO2010132521A1/en not_active Ceased
-
2015
- 2015-06-04 JP JP2015113773A patent/JP2015180673A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012526832A5 (enExample) | ||
| JP2010529118A5 (enExample) | ||
| AR079542A1 (es) | Derivados de benzamida sustituidos, proceso para su preparacion y su uso en el tratamiento de enfermedades mediadas por taars. | |
| CU20150180A7 (es) | Piridin-2 que contienen il-4-derivados sustituidos de 1-diazino fenilo útiles como ligandos de dopamina | |
| JP2007516941A5 (enExample) | ||
| Thomas et al. | The pharmacology of Tourette syndrome | |
| MX394941B (es) | Métodos y composiciones para el tratamiento de apnea del sueño | |
| JP2015501783A5 (enExample) | ||
| CL2008001215A1 (es) | Compuestos derivados de heterociclos nitrogenados condensados; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, dislipidemia, obesidad y alzheimer. | |
| BRPI1011220A2 (pt) | composição farmacêutica, métodos para tratar uma doença ou distúrbio, para administração respiratória de dois ou mais agentes ativos, para administração respiratória de uma combinação de agentes ativos, e, para preparar uma composição adequada. | |
| ECSP12012098A (es) | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos para utilizar los mismos | |
| NZ630260A (en) | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same | |
| CL2008002864A1 (es) | Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros. | |
| JP2013525444A5 (enExample) | ||
| WO2014120936A3 (en) | Treatments for depression and other diseases with a low dose agent | |
| JP2015521642A5 (enExample) | ||
| JP2009541443A5 (enExample) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| NZ582925A (en) | Use of bubropion hydrobromide for the prevention of seizures associated with bupropion administration | |
| JP2020503246A5 (enExample) | ||
| WO2012138599A3 (en) | Hepatocyte growth factor mimics as therapeutic agents | |
| EA201590406A1 (ru) | Мочевинные и амидные производные аминоалкилпиперазинов и их применение | |
| CL2011000137A1 (es) | Uso de compuestos derivados de 4,5-dihidro-oxazol-2-ilamina para tratar trastornos de ansiedad, trastornos bipolar, esquizofrenia, enfermedades neurológicas, epilepsias, migraña, trastornos metabólicos, trastornos cardiovasculares, entre otros; compuestos derivados de 4,5-dihidroxazol-2-ilamino; proceso de síntesis | |
| CL2012002540A1 (es) | Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras. | |
| JP2008511569A5 (enExample) |